Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

107.95 -0.76 (-0.70%)
Streaming Delayed Price Updated: 12:54 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Illumina (ILMN) To Report Earnings Tomorrow: Here Is What To Expect
Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Illumina (ILMN) Stock Is Up, What You Need To Know
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.... 
Via StockStory
Topics Artificial Intelligence
12 Analysts Assess Illumina: What You Need To Know
 
Via Benzinga
1 Profitable Stock with Exciting Potential and 2 We Question
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Illumina Stock: What Went Wrong And Why It's Best To Stay Away
According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why. 
Via Benzinga
Why Illumina (ILMN) Shares Are Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target. 
Via StockStory
Topics Government World Trade
Where Illumina Stands With Analysts
 
Via Benzinga
Illumina (ILMN) Stock Trades Down, Here Is Why
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.6% in the afternoon session after the major indices pulled back (Nasdaq -0.8%, S&P 500 -0.77%), largely due to escalating concerns surrounding... 
Via StockStory
Topics Artificial Intelligence Government Stocks
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
From iRhythm
Via GlobeNewswire
5 Must-Read Analyst Questions From Illumina’s Q1 Earnings Call
Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance fell short of market expectations, prompting a negative reaction from... 
Via StockStory
Topics Earnings World Trade
“Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz”
Via AB Newswire
Topics Artificial Intelligence
SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push
Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in multiomics. 
Via Benzinga
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Energy
3 Reasons ILMN is Risky and 1 Stock to Buy Instead
What a brutal six months it’s been for Illumina. The stock has dropped 33.6% and now trades at $89.03, rattling many shareholders. This may have investors wondering how to approach the situation. 
Via StockStory
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Breaking Down Illumina: 11 Analysts Share Their Views
 
Via Benzinga
3 Mid-Cap Stocks Walking a Fine Line
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
ILMN Q1 Earnings Call: Clinical Growth and Cost Actions Offset Research and China Headwinds
Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per... 
Via StockStory
Topics Economy World Trade
Cathie Wood Sells Tesla Stock As Chinese Rivals Gain Ground — Ark Dumps Palantir Amid Privacy Concerns
On Monday, Cathie Wood-led Ark Invest sold shares of Tesla and Palantir, amidst competition and data misuse concerns. Ark also made significant trades in other companies, such as eToro and Illumina. 
Via Benzinga
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit
Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham. 
Via Benzinga
Topics Artificial Intelligence
Life Sciences Tools & Services Stocks Q1 Recap: Benchmarking Illumina (NASDAQ:ILMN)
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Danaher, Illumina, Globalstar, and Insperity Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the major indices fell further in the afternoon (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft... 
Via StockStory
Topics Bonds Stocks
What 15 Analyst Ratings Have To Say About Illumina
 
Via Benzinga
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025. 
Via Benzinga
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings. 
Via Benzinga
3 Volatile Stocks with Mounting Challenges
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared. 
Via StockStory
Illumina Analysts Lower Their Forecasts After Q1 Results
 
Via Benzinga
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.